Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
| Status: | Completed |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/17/2018 |
| Start Date: | March 10, 2011 |
| End Date: | June 28, 2018 |
A Randomized Phase 4 Study Comparing 2 Intravenous Temsirolimus (Temsr) Regimens In Subjects With Relapsed, Refractory Mantle Cell Lymphoma
This study will compare the effectiveness and safety of two different doses of temsirolimus
(Torisel).
(Torisel).
Inclusion Criteria:
- Have confirmed mantle cell lymphoma diagnosis.
- Have measurable disease.
- Have received at least 2 prior treatment, which may include stem cell transplant.
- Have adequate organ and bone marrow function.
- There are other criteria--please discuss with your doctor.
Exclusion Criteria:
- Had any prior treatment with temsirolimus or mTOR inhibitor.
- Had allogeneic stem cell transplant within last 6 months and on immunosuppressive
therapy.
- Has active or untreated brain or central nervous system metastases.
- There are other criteria--please discuss with your doctor.
We found this trial at
7
sites
East Orange, New Jersey 07018
Click here to add this to my saved trials
VA Puget Sound Health Care System With a reputation for excellence, innovation and extraordinary care...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73120
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials